Macquarie Group LTD Cytom X Therapeutics, Inc. Transaction History

Macquarie Group LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$1.41 - $2.74 $1,598 - $3,107	1,134 New	1,134 $2,000
Q4 2021 Feb 11, 2022	SELL	$3.87 - $7.39 $18,781 - $35,863	-4,853 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$4.32 - $6.43 $17,556 - $26,131	4,064 Added 515.08%	4,853 $25,000
Q1 2021 May 14, 2021	SELL	$6.6 - $9.0 $2,468 - $3,366	-374 Reduced 32.16%	789 $6,000
Q2 2020 Aug 11, 2020	BUY	$7.4 - $14.64 $8,606 - $17,026	1,163 New	1,163 $10,000
Q3 2018 Nov 15, 2018	SELL	$18.04 - $26.41 $12,628 - $18,487	-700 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$21.38 - $29.68 $14,966 - $20,776	700 New	700 $16,000
Q1 2018 May 11, 2018	SELL	$21.76 - $34.22 $478,720 - $752,840	-22,000 Closed	0 $0
Q4 2017 Feb 15, 2018	BUY	$19.0 - $23.09 $305,900 - $371,749	16,100 Added 272.88%	22,000 $464,000
Q3 2017 Nov 08, 2017	BUY	$13.53 - $18.17 $79,827 - $107,203	5,900	5,900 $107,000

50.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $66M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.